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Strengths and limitations of this study
 ► This will be the first systematic review to pool re-
tention rates in randomised controlled trials of 
outpatient smoking interventions for persons with 
a mental health disorder and explore associated 
factors.
 ► Identification of participant, environmental, re-
searcher and study factors associated with retention 
will be informative when designing future smoking 
intervention trials for persons with a mental health 
disorder and may lead to increased retention and, in 
turn, rigour of research in the field.
 ► It will employ Cochrane’s methods for the conduct of 
systematic reviews.
 ► Trials of smoking interventions delivered exclusively 
in psychiatric inpatient setting will not be included.
AbStrACt
Introduction Smoking among persons with a mental 
health disorder is associated with inequitable health, 
social and economic burden. Randomised controlled 
trials (RCTs) are considered the gold standard design 
for the assessment of healthcare intervention efficacy/
effectiveness. However, many RCTs of smoking 
interventions for persons with a mental health disorder 
lack rigour due to low participant retention. No systematic 
review has pooled retention rates in randomised trials of 
smoking interventions for persons with a mental health 
disorder or explored associated factors. The aims of the 
systematic review will therefore be to: (1) summarise 
overall rates of participant retention in smoking cessation 
and reduction trials involving persons with a mental health 
disorder (including for experimental and control groups 
separately) and (2) determine if retention rates vary 
according to participant, environmental, researcher and 
study factors.
Methods and analysis PsycINFO, EMBASE, MEDLINE, 
CENTRAL and The Cochrane Tobacco Addiction Review 
Group Specialised Register will be searched for reports 
of RCTs of outpatient smoking cessation or reduction 
interventions for adults with a mental health disorder. 
The search terms will include MeSH terms and free text 
words, and there will be no language or date restrictions. 
All databases will be searched from inception to present. 
Data will be analysed using the Mantel-Haenszel fixed-
effect model, and where substantial heterogeneity (I2 
>50%) is detected, DerSimonian & Laird inverse-variance 
random effects model. Pooled estimates and 95% CIs 
will be calculated for overall participant retention rates 
and for intervention and control trial arms separately. 
Associations between participant retention and participant, 
environmental, researcher and study factors will be 
assessed via subgroup analyses and, where sufficient data 
are obtained, meta-regression.
Ethics and dissemination This study does not require 
ethical approval. The findings of this review will be 
disseminated via publication in a peer-reviewed open 
access medical journal and presentations at international 
scientific meetings.
IntroduCtIon
Tobacco smoking is a leading cause of 
preventable morbidity and mortality world-
wide.1 Smoking prevalence has steadily 
declined to between 13% and 20% over the 
past 40 years in the general population of 
high-income countries;2–4 however, it has 
remained unchanged among persons with a 
mental health disorder.5 6 Population surveys 
suggest that 40%, 44% and 36% of commu-
nity residing persons with a mental health 
disorder in the USA,7 UK8 and Australia7 
smoke, respectively, with prevalence esti-
mates shown to increase as mental illness 
severity and number of life time disorders 
increase.9 10 These groups are also reported 
to smoke more heavily and be more nicotine 
dependent than smokers without a mental 
health disorder9–11 and have been estimated 
to consume up to 45% of all cigarettes sold in 
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persons with a mental health disorder is consequently 
associated with inequitable health, social and economic 
burden.14 Despite this, many high-quality randomised 
trials of smoking interventions exclude persons with 
a mental health disorder15 16 and those focused on this 
population group often lack rigour due to, for example, 
small sample size and low participant retention.17–19 More 
rigorous intervention research is needed to address this 
international public health issue.20 21
Randomised controlled trials (RCTs) are considered 
the gold standard design for assessment of healthcare 
intervention efficacy and effectiveness.22 In any trial, low 
rates of participant retention for follow-up data collection 
can compromise the internal and external validity and 
reduce statistical power.23–25 Threats to internal validity 
are particularly salient as retention decreases (<80%25) 
or is differential between allocation groups,26 increasing 
the risk of bias and confounding.26 Additionally, statis-
tical methods (eg, multiple imputation) cannot account 
entirely for the impact of low/differential retention and 
have been noted to occasionally be used inappropri-
ately.27 Illustrating a consensus regarding the need to 
consider and address the issue of low retention in clin-
ical and health behaviour trials: the inclusion of items on 
participant retention in the Consolidated Standards of 
Reporting Trials (CONSORT) statement,28 29 and prior-
itisation of trial methodology research to develop novel 
approaches to increase retention in randomised trials.30 31 
In addition, the emergence of recent systematic reviews 
examining retention rates in health behaviour studies32–36 
and publication of retention data from high quality 
randomised trials37–39 indicates increased interest in the 
topic of retention and a recognition of its importance.
Participant retention is problematic in trials of smoking 
cessation interventions,40 41 including those involving 
persons with a mental health disorder.17–19 For example, 
review of risk of bias assessments in systematic reviews of 
smoking cessation intervention trials involving persons 
with depression17 and substance use disorders19 revealed 
retention rates as low as 27%–33%, at trial end points. In 
addition, 65 of the trials (34/49;17 31/3519) included in 
the reviews transparently reported on participant reten-
tion, of which 40 (22/34;17 18/3119) achieved retention 
rates less than 80%. In addition, there was evidence of 
differential retention (≥10% difference in retention rates 
between allocation groups) in 13 (5/34;17 8/3119) trials, 
with this figure likely an underestimate due to non-sys-
tematic reporting of retention data according to alloca-
tion group. No study has systematically and quantitatively 
summarised retention rates of persons with a mental 
health disorder in smoking trials or considered factors 
that may impact on such rates.
Factors likely to impact participant retention in any 
trial could be categorised into four types: (1) ‘participant’ 
(eg, demographic information) (2) ‘environmental’ (eg, 
recruitment method/setting) (3) ‘researcher’ (eg, staff 
qualifications) and (4) ‘study’ (eg, trial design).42 In terms 
of participant factors, evidence from single studies in the 
field of smoking and mental illness suggests younger age, 
higher income, less severe mental health symptomology 
and readiness to quit at baseline may be associated with 
higher retention in trials.37 39 43 44 While no research has 
reported on environmental and researcher factors asso-
ciated with retention in smoking trials involving persons 
with a mental health disorder, findings from the broader 
field of smoking research suggest that higher reten-
tion rates are observed when proactive (compared with 
reactive) recruitment methods are adopted,40 and staff 
delivering the intervention receive more comprehensive 
training.29 With regard to study factors, Cochrane system-
atic review evidence suggests open-label designs increase 
the relative risk of higher retention rates (risk ratio (RR) 
1.37; 95% CI 1.16 to 1.63) in randomised trials of health 
interventions outside the field of smoking.33 Further, 
adoption of strategies with demonstrated effectiveness 
in improving retention in health research could also be 
considered a ‘study’ factor. Such strategies were devel-
oped based on identified barriers to participant reten-
tion32 and include monetary reimbursement for time,45 
provision of reminders for follow-up assessments46 and 
participant tracking systems.46 Identification of partici-
pant, environmental, researcher and study factors asso-
ciated with higher participant retention in smoking trials 
involving persons with a mental health disorder will be 
informative for researchers when designing definitive 
trials and in turn potentially improve the rigour of avail-
able intervention research in the field.
No review has systematically examined rates of 
participant retention or explored associated factors in 
smoking cessation and/or reduction trials involving 
persons with a mental health disorder. Therefore, the 
aims of the proposed systematic review will be to: (1) 
summarise overall rates of participant retention in such 
trials (including for experimental and control groups 
separately) and (2) determine if retention rates vary 
according to participant, environmental, researcher and 
study factors.
MEthodS
This protocol adheres to the preferred reporting items 
for systematic review and meta-analysis protocols (PRIS-
MA-P) statement.47
Inclusion criteria
Studies identified by a Cochrane review of outpatient 
smoking cessation and reduction interventions for 
persons with a mental health disorder48 will be included. 
Criteria for inclusion:
 ► Study design: RCTs and cluster RCTs.
 ► Participants: adult (aged 18 years or above) 
smokers, who have either been diagnosed with a 
mental health disorder (determined via medical 
record or self-report) in the past 12 months or are 
currently receiving treatment for the same. Partici-
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quit smoking to be eligible. No limits will be placed 
on recruitment setting; however, the majority of 
the intervention component must be delivered in 
a community setting. Interventions delivered exclu-
sively during an inpatient psychiatric admission 
will be excluded as they are the focus of another 
Cochrane review.49
 ► Intervention type: any intervention to aid smoking 
cessation or reduction, for example, pharmaco-
therapy, psychoeducation, cognitive and behavioural 
therapies. Interventions aiming to increase the 
uptake/utilisation of smoking cessation supports will 
be considered. However, whole-of-setting interven-
tions (eg, smoke-free policy) will be excluded.
 ► Intervention delivery: face-to-face, telephone, online, 
mail, individual and/or group. Interventions can 
be facilitated by any person (eg, research officer or 
healthcare clinician) or via unmoderated online/
phone-based methods.
 ► Control: all control conditions will be considered, for 
example, placebo, no treatment, usual care, other 
smoking cessation/reduction interventions.
 ► Follow-up: undertaken at least 6 months postbaseline 
assessment.50
Search strategy
The following databases will be searched for reports of 
trials of smoking cessation and reduction interventions 
among smokers with a mental health disorder:
 ► The Cochrane Tobacco Addiction Review Group 
Specialised Register.
 ► Cochrane Central Register of Controlled Trials 
(CENTRAL).
 ► MEDLINE (OVID SP 1946 to present) & MEDLINE 
in-process & other non-indexed citations (OVID SP).
 ► EMBASE (OVID SP, 1947 to present).
 ► PsycINFO (OVID SP,1806 to present).
Search terms will include MeSH terms and free text 
words, and there will be no language or date restrictions. 
All databases will be searched from inception to present. 
Reference lists of included studies will be checked for 
other relevant research. Online supplementary appendix 
1 comprises the proposed Medline search strategy. 
Searches will likely be undertaken in December 2019.
In addition to the above, we will search international 
clinical trials registers for recently completed trials, 
including: the Australian and New Zealand Clinical Trials 
Registry (ANZCTR), UK Clinical Trials Gateway; US Clin-
ical Trials Register and the WHO Portal.
Study screening and data extraction
Two review authors will independently screen the titles 
and abstracts of search results for relevance, acquire 
and screen the full texts of potentially eligible articles 
and extract data from included studies. Disagreements 
during the screening and data extraction processes will 
be resolved by referral to a third review author. Covidence 
(https://www. covidence. org/ home) and Microsoft 
Excel will be used to manage data during screening and 
extraction phases.
Data to be extracted from included trials are outlined 
in table 1, with independent variables for consideration 
identified in the respective column and summarised 
under relevant headings below. A large number of poten-
tial independent variables could be considered, selection 
will be guided by extant literature, experts in the field 
and, with exception of ‘participant factors’, focus on 
factors modifiable by researchers.
Participant factors
Participant characteristics for consideration, collected 
at the baseline assessment of individual studies, may 
include: age,39 40 gender,40 43 race/ethnicity,40 socioeco-
nomic status,40 mental health diagnosis,37 severity of 
distress,13 motivation/readiness to quit smoking,40 44 nico-
tine dependence,30 40 daily cigarette consumption40 49 and 
requirement to set a quit date on recruitment.40
Environmental factors
Environmental factors comprise those related to the study 
setting. Such factors that may be considered include the 
method40 and setting51 of recruitment and outcome data 
collection.
Researcher factors
Researcher factors include characteristics, skills and roles 
of the staff that design and implement the study and may 
include: recruiter qualifications, training and professional 
role51 52 and relationship of recruiter to participants.51
Study factors
Study factors comprise features of the study design and 
implications of such for participants. A number of study 
factors may be considered: blinding/masking of research 
personnel,33 adoption of retention strategies,32 37 timing 
of follow-up assessments,39 40 biochemical validation of 
self-reported abstinence and potential cost/s to partici-
pants of follow-up assessment completion.32 51
outcomes
The primary outcome of interest for the review is partici-
pant retention rate at the longest follow-up. Within each 
study, retention will be defined as participation in the 
final follow-up assessment of a trial (eg, completion of 
telephone or face-to-face interview or response to postal 
and electronic questionnaires). Retention rate will be 
calculated using the formula: number retained/number 
recruited. Study authors will be approached to obtain data 
required to calculate outcome measures, if not reported 
in the published manuscript. Secondary analyses will 
explore follow-up rates separately at other time points, 
for example, at 6 months, 12 months and 18 months.
Analysis
Data will be analysed using Review Manager 5.3 and 
Stata 15.0. Outcome data will be collected in accordance 
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Table 1 Data extraction fields





Author First author last name
Year Year published
Title Title of publication
Country From text
Years of study Year/s study was conducted
Funding source From text
Conflict of interests From text
Methods
Study design RCT, cluster RCT
Aims of study From text
Years of recruitment Years
Method of recruitment Face-to-face, social media, random-digit dialling;; snowball 
recruiting; use of social networks; advertisements, media or 
notices ; identification of potential participants through public 
registries, medication record and so on
Yes
Recruitment setting Hospital, community healthcare, primary care, non-government 
organisation (NGO), other
Yes
Recruiter qualifications, training and 
professional role
  Yes
Familiarity of recruiter to participant Unknown (eg, external researcher), limited previous contact (eg, 
staff member in hospital), regular clinician, peer, other
Yes
Retention strategy employed Yes/no; type Yes
Participants
Age Mean (standard deviation), median (range) Yes
Gender Male, female, other/unspecified. Yes
Race/ethnicity From text Yes
Socio-economic status Employment status, level of education or similar Yes
Mental health diagnosis Type of mental illness/es of participants Yes
Severity of distress/ mental health disorder DASS-21, Kessler 10, Global Assessment of Functioning (GAF) 
or similar measures
Yes
Inclusion/exclusion criteria From text
Current smoker definition Daily, weekly, occasional smoker Yes
Cigarette consumption (baseline) Mean (standard deviation), median (range) Yes
Nicotine dependence (baseline) Fagerstrom Test of Nicotine Dependence (FTND) or similar 
measures
Yes
Motivation to quit (baseline) Readiness and Motivation to Quit Smoking Questionnaire or 
similar measures
Yes
Requirement to set a quit date on recruitment Yes/no Yes
Intervention
Treatment type Pharmacotherapy, psychoeducation, cognitive and behavioural 
therapies, staff training, other
Dosage (if applicable)   
Duration Weeks
Number of session (where applicable)   
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Mode of delivery Face-to-face, telephone, online, mail, individual and/or group, 
other
Description of comparator Placebo, no treatment, waitlist, usual care, other smoking 
cessation/reduction intervention, other
Outcomes
Primary outcomes Specified and collected
Secondary outcomes Specified and collected
Definition of abstinence From text
Definition of smoking reduction From text
Type of biochemical validation (if applicable) Carbon monoxide (CO), cotinine, other Yes
Timing of follow-up assessments Months Yes
Mode of follow-up assessment Face-to-face, telephone interview, postal or electronic survey 
and so on
Yes
Follow-up setting (if applicable)   Yes
Potential costs to participant associated with 
follow-up assessments
Absence from work, fuel and parking costs and so on Yes




Method of randomised sequence generation   
Method of allocation concealment   
Blinding of participants Yes/no Yes
Blinding of research staff Yes/no Yes
Blinding of outcome assessors Yes/no Yes
Levels of loss to follow-up   
Reporting of loss to follow-up   
GRADE GRADE methodology rating
Table 1 Continued
participants will be included in denominator figure of the 
retention algorithm. Data that are missing due to partici-
pant death will be deducted from the total sample size for 
all analyses.
According to study aim
Aim 1: the proportion of participants retained will 
be pooled using the Stata 15.0 prevalence command, 
‘metaprop’ using the Freeman-Tukey double arcsine trans-
formation to stabilise variances and prevent exclusion 
of studies where proportions approached 0 or 1.53 54 We 
will calculate pooled estimates and 95% CIs for overall 
participant retention rates as well as for intervention and 
control trial arms separately. Differences between inter-
vention and control arms will be assessed via risk ratios. 
Data will be analysed using the Mantel-Haenszel fixed-ef-
fect model. If substantial heterogeneity (I2>50%)50 is 
detected in the pooled estimates, we will run sensitivity 
analyses using DerSimonian & Laird inverse-variance 
random effects meta-analysis.55
Aim 2: the association between participant, environ-
mental, researcher and study factors and overall partici-
pant retention will be assessed via subgroup analyses and, 
where sufficient data are obtained (>10 observations),50 
meta-regression. Subgroup analyses will be undertaken in 
line with the meta-analysis approach described for Aim 
1. Independent variables (table 1) will be categorised 
and reduced to two or three levels for the purpose of this 
analysis. In terms of the meta-regression, we will build 
models using the ‘regress’ and, where relevant, ‘metareg’ 
commands. Study level weights will be obtained from 
the fixed effects meta-analysis and will be included in the 
regression models using the analytical weights option. 
Categorical and numerical independent variables to be 
considered in these models. Ratio data will be natural 
log transformed prior to analyses. Where data are not 
amenable to meta-analysis, factors reported in individual 
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Statistical heterogeneity and sensitivity analyses
The I2 statistic, which describes the percentage of total 
variation across studies that is due to heterogeneity rather 
than chance, will be used to assess statistical heteroge-
neity of pooled data. Heterogeneity in pooled estimates 
will be described as low (I2~25%), moderate (I2~50%) or 
high (I2~75%).56 Sensitivity analyses will be conducted to 
explore the impact of including studies with an overall 
high risk of bias.
Patient and public involvement
Patients/public were not involved at any stage in the 
development of this protocol.
dISCuSSIon
This rigorous systematic review will be the first to pool 
retention rates in RCTs of outpatient smoking interven-
tions for persons with a mental health disorder. Identi-
fication of participant, environmental, researcher and 
study factors associated with retention will be informative 
when designing future smoking intervention trials for 
persons with a mental health disorder, and in turn, may 
lead to increased rigour of research in the field due to 
higher participant retention. Findings may not generalise 
to trials of smoking interventions delivered exclusively in 
psychiatric inpatient settings.
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